bluebird bio Announces Closing of Initial Public Offering and Exercise of Over-Allotment Option
June 24, 2013 at 16:07 PM EDT
bluebird bio (NASDAQ: BLUE ), a clinical-stage biotechnology company focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy, today announced the closing of its initial public offering of 6,832,352 shares of common stock at an initial public offering price of $17.00 per
